南方周末发布的2026年度医药制造业企业科创力排名显示,中国制药行业头部企业的座次发生显著变化 1。百济神州以73.62分的总成绩超越恒瑞医药(67.11分),夺得榜首位置,两者分差扩大至6.51分 1。复星医药凭借54.88分重新位列第三,而石药集团的排名则滑落至第六位,得分为51.39分 1。
这一排名变动反映了中国制药行业正经历从“仿制替代”向“全球创新”的关键转型 1。分析指出,百济神州的崛起主要得益于其在研发投入上的高强度以及全球商业化的成功落地 1。具体而言,其核心产品泽布替尼在ALPINE试验中展现了头对头优于伊布替尼的疗效优势;与此同时,康方生物的依沃西也在HARMONi-2试验中战胜帕博利珠单抗,凸显了本土创新的竞争力 1。
尽管面临更激烈的竞争环境,恒瑞医药的转型成效显著,目前拥有26款1类创新药,且创新药收入占比已超过六成 1。在行业整体层面,2025年中国创新药的对外授权交易总额突破1300亿美元,标志着中国企业正逐步从单纯的管线供应商转变为全球价值创造的合伙人 1。进入2026年上半年,相关BD首付款达到49.75亿美元,同比增长71.65%,进一步印证了这一趋势 1。
Southern Weekly has released its 2026 Science and Technology Innovation Power ranking for pharmaceutical manufacturing enterprises, marking a significant shift in the industry's leadership hierarchy 1. BeiGene secured the top spot with a total score of 73.62, surpassing former leader Hengrui Medicine, which scored 67.11 1. The gap between the two companies widened to 6.51 points this year, reflecting changing dynamics among China's leading drugmakers 1. Fosun Pharma reclaimed third place with a score of 54.88, while CSPC Pharmaceutical Group slipped to sixth position with 51.39 points 1.
This reshuffling underscores the Chinese pharmaceutical sector's transition from generic substitution to global innovation 1. BeiGene’s rise is attributed to substantial R&D investment and successful global commercialization efforts, exemplified by its BTK inhibitor zanubrutinib demonstrating head-to-head superiority over ibrutinib in the ALPINE trial 1. Similarly, Akeso’s ivonescimab outperformed pembrolizumab in the HARMONi-2 study, highlighting broader competitive advantages 1. Meanwhile, Hengrui Medicine continues to show strong transformation results, with innovative drugs accounting for over 60% of its revenue and a portfolio of 26 Class 1 innovative drugs, though it faces intensifying competition 1.
The industry’s growing influence on the global stage is further evidenced by record-breaking external licensing deals. In 2025, outbound license transactions for Chinese innovative drugs exceeded $130 billion, signaling a strategic evolution from pipeline suppliers to global value creation partners 1. This momentum continued into the first half of 2026, where upfront payments for business development deals reached $4.975 billion, representing a year-on-year increase of 71.65% 1.
评论
还没有评论,欢迎留下第一条。